Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study

Abstract : Neoadjuvant chemotherapy has become the treatment of choice for locally advanced breast cancer. Zoledronic acid (ZA) is a bisphosphonate initially used in the treatment of bone metastases because of its antibone resorption effect. Antitumor effects of ZA, including the inhibition of cell adhesion to mineralized bone or the antiangiogenic effect, have been demonstrated. However, the clinical significance of these effects remains to be determined.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01930003
Contributor : Mouniati Colo <>
Submitted on : Wednesday, November 21, 2018 - 3:11:50 PM
Last modification on : Thursday, November 22, 2018 - 1:18:42 AM

Identifiers

Collections

Citation

Loïc Lelièvre, Philippe Clézardin, Laurent Magaud, Laurent Roche, Nicole Tubiana-Mathieu, et al.. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer, Elsevier, 2018, ⟨10.1016/j.clbc.2018.07.005⟩. ⟨hal-01930003⟩

Share

Metrics

Record views

19